Mathias Romacker Selected as the Newest Member of the Kymanox Executive Advisor Team

Kymanox Corporation (“Kymanox”), a professional services organization supporting biotechnology, pharmaceutical, medical device, and combination product industries, announced the addition of well-known and experienced professional, Mathias Romacker, to the Kymanox Executive Advisor (KEA) team.

With its diverse team of industry experts, Kymanox helps clients navigate commercialization challenges that arise throughout a product’s life cycle – from early development to post-market. Kymanox Executive Advisors provide strategic guidance to the company and leverage deep relationships in the global life science community to help the company’s clients and their programs achieve success .

With over 30 years of experience in the biopharma, pharmaceutical supplier, and medical device industries, Romacker served four times as the co-chair of the largest combination products conference of the year, the PDA Universe of Prefilled Syringes & Injection Devices Conference. He is the former Senior Director of Device Strategy at Pfizer and currently is a Board Member for the Parenteral Drug Association (PDA) and will continue to serve in that capacity for 2023.  Romacker originated the concept and project initiation of the game-changing Neulasta® on-body-injector, called Onpro®.

“We are thrilled and honored to have Mathias, a global powerhouse and influential leader in our industry, support our vision of helping pharmaceutical and biotech companies bring products to the market to impact and enhance patients’ lives,” stated Evan Edwards, Chief Innovation Officer at Kymanox.

Romacker was previously employed by both operating pharmaceutical companies as well as suppliers to the industry, and his profound understanding of both perspectives enables him to identify strong market opportunities for combination products. As an industry leader, he offers significant expertise in several areas including, but not limited to:

  • Combination Products and Device Strategy
  • Device Portfolio Management
  • Executive Leadership and Business Development
  • Pharmaceutical and Device Packaging

“Mathias truly exemplifies what Kymanox is all about, and we are honored to have him join our work family as our first ever California-based team member,” said Stephen M. Perry, CEO and Founder of Kymanox. “Clients and partners alike will benefit significantly from his added strategic advice and strong industry network.”

Romacker holds a Graduate Degree in Economics from Freiburg University in Germany.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.